Newsroom

Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes Adds Multi-Disciplinary Team and Capabilities Harnessing the Power of Next-Generation Sequencing (NGS), Population Scale Clinical Studies, and Machine Learning to Address One of Medicine’s Greatest Challenges Brings Significant New Growth Opportunities in the Clinical Setting […]

View Full Release

News Releases

Company News

Fact Sheets

Explainer Videos

Media Kit

GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah

View Full Release

PGA TOUR Champions and GRAIL Announce The Galleri® Classic

View Full Release

GRAIL and Point32Health Collaborate to Offer Galleri® Multi-Cancer Early Detection Blood Test

View Full Release

GRAIL Statement on President Biden’s Bold Initiative to Reignite the Cancer Moonshot

View Full Release

Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test

View Full Release

GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

View Full Release

GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test

View Full Release

GRAIL Receives New York State Approval for Galleri Multi-Cancer Early Detection Blood Test

View Full Release

NHS Launches UK Trial of the Galleri Multi-Cancer Early Detection Blood Test

View Full Release

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

View Full Release

GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test

View Full Release

Statement on the Passing of Dr. José Baselga, from his friends at GRAIL

View Full Release

GRAIL, AccessHope Collaborate to Optimize Patient and Healthcare Provider Experience for Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

View Full Release

GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test

View Full Release

Multi-Cancer Early Detection Company GRAIL Now Hiring For State-Of-The-Art Laboratory Facility in Research Triangle Park

View Full Release

GRAIL and Quest Diagnostics Announce Collaboration to Support Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

View Full Release

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

View Full Release

GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

View Full Release

New Research Suggests Multi-Cancer Early Detection Blood Test Could Reduce Late-Stage Cancer Diagnoses by More Than Half

View Full Release

GRAIL and UK Government to Make Galleri Multi-Cancer Early Detection Blood Test Available to Patients

View Full Release

Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

View Full Release

GRAIL Announces Filing of Registration Statement for Proposed Initial Public Offering

View Full Release

Cleveland Clinic Joins Interventional Study Using GRAIL's Multi-Cancer Early Detection Test to Help Guide Clinical Care

View Full Release

GRAIL to Present New Data Supporting its Multi-Cancer Early Detection Test at the American Association for Cancer Research (AACR) Annual Meeting II

View Full Release

GRAIL Stands Against Injustice and Racism

View Full Release

NC Gov. Cooper: Governor Cooper Announces Nearly 400 New Jobs in Durham as Multi-Cancer Early Detection Company Chooses New Laboratory Location

View Full Release

GRAIL to Participate in BofA Securities 2020 Health Care Conference

View Full Release

GRAIL Announces $390 Million Series D Financing

View Full Release

Mostafa Ronaghi Joins GRAIL’s Board of Directors

View Full Release

GRAIL Appoints Satnam Alag as Senior Vice President of Software Engineering

View Full Release

GRAIL to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting

View Full Release

GRAIL Appoints Sir Harpal Kumar as President of GRAIL Europe

View Full Release

GRAIL Announces Validation of its Multi-Cancer Early Detection Test Published in Annals of Oncology

View Full Release

GRAIL Initiates First Interventional Study Using its Multi-Cancer Early Detection Test to Guide Clinical Care

View Full Release

GRAIL Appoints Gautam Kollu as Chief Commercial Officer

View Full Release

GRAIL Appoints Matthew Young as Chief Operating Officer and Chief Financial Officer

View Full Release

GRAIL Announces Positive Validation Data for its Multi-Cancer Early Detection Test

View Full Release

GRAIL Appoints Marissa Song as General Counsel and Corporate Secretary

View Full Release

GRAIL to Present New Data in Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) 2019 Congress

View Full Release

GRAIL Appoints Rodger Currie as Head of Government Affairs and Alliance Development

View Full Release

GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer and Strengthens Leadership Team and Board of Directors with New Appointments

View Full Release

GRAIL Announces Positive New Data with Multi-Cancer Early Detection Blood Test from CCGA Study

View Full Release

GRAIL Announces Promising New Data with Early Detection Blood Test to be Presented at 2019 American Society of Clinical Oncology Annual Meeting

View Full Release

GRAIL Announces Significant Progress with Multi-Cancer Early Detection Test Including FDA Breakthrough Device Designation

View Full Release

GRAIL Announces Appointment of Catherine Friedman as Chair of GRAIL Board

View Full Release

GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection

View Full Release

GRAIL to Present New Data from the Circulating Cell-free Genome Atlas (CCGA) Study at the European Society for Medical Oncology (ESMO) 2018 Congress

View Full Release

GRAIL Announces Appointment of Renée Galá as Chief Financial Officer

View Full Release

GRAIL Announces Appointment of Hal Barron and Hans Bishop to its Board of Directors

View Full Release

GRAIL Announces Appointment of Key Executives as Company Makes Continued Progress in Development of Early Detection Products

View Full Release

GRAIL Announces Data on Detection of Early-Stage Lung Cancers

View Full Release

GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing

View Full Release

GRAIL to Present New Data from Circulating Cell-free Genome Atlas (CCGA) Study at 2018 American Society of Clinical Oncology Annual Meeting

View Full Release

GRAIL Announces Data from Prototype Blood Tests for Early Cancer Detection

View Full Release

GRAIL Announces Appointment of Jennifer Cook as Chief Executive Officer

View Full Release

GRAIL Appoints Chairman Bill Rastetter to Chief Executive Officer

View Full Release

GRAIL Announces Data From Early Research Analyzing its High-Intensity Sequencing Approach

View Full Release

GRAIL Announces Board of Directors Appointments

View Full Release

GRAIL Initiates the STRIVE Study to Advance Development of Blood Tests to Detect Cancer Early

View Full Release

GRAIL and Cirina Combine to Create Global Company Focused on Early Detection of Cancer

View Full Release

GRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early

View Full Release

GRAIL Plans to Raise in Excess of $1B in Series B Funding

View Full Release

GRAIL Announces Circulating Cell-free Genome Atlas (CCGA) Study as Foundation for Development of Blood Test to Detect Cancer Early

View Full Release

GRAIL Hires Google Executive Jeff Huber as CEO to Lead Development for Early Cancer Detection

View Full Release

Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening

View Full Release

GRAIL Named “Best Overall Medical Device Company” in 2022 MedTech Breakthrough Awards

GRAIL’s Galleri Multi-Cancer Early Detection Test Named in Fast Company’s 2022 World Changing Ideas Awards List

April 2022 Business Update

New Blood Test Could Change the Way Cancer is Detected

12/20/2021 | NBC News

Catching cancer extremely early

03/26/2021 | Science Magazine

This New Blood Test Can Detect 50 Types of Cancers

03/17/2021 | Healthline

A New Early-Detection Blood Test Marks a Leap Forward in the War on Cancer

01/21/2021 | Fast Company

AJMC, Novel Multicancer Early Detection Technology—Potential Value to Employers and the Workforce

12/18/2020 | AJMC

A Novel Early Detection Blood Test Could Soon Change How Cancer is Found

The Guardian view on a new test for cancer: grounds for optimism

12/01/2020 | The Guardian

Taking Early Cancer Detection to the Next Level

11/01/2020 | Scientific American

Can a blood test detect cancer in asymptomatic patients?

10/28/2020 | CURE Magazine

The Cancer Detection Rate--a Public Health Approach to Early Detection

10/02/2020 | The Cancer Letter

Cancer Screening Leaps Forward

07/05/2020 | WSJ

Entering a New Era of Early Cancer Detection

Working to Transform Cancer Care Through Early Detection

Striving for Earlier Cancer Detection

The PATHFINDER Study

Download Fact Sheet

Galleri Development Timeline

Download Fact Sheet

What is the Galleri test?

Download Fact Sheet

GRAIL Corporate Fact Sheet

Download Fact Sheet

Multi-Cancer Early Detection Fact Sheet

Download Fact Sheet

GRAIL Methylation

It is our capability and our commitment that make us GRAIL

Logos

Download GRAIL Logo

Download Galleri Logo

Images

B-Roll

Download B-Roll

Contact us

Contact Public Relations

pr@grail.com

1525 O'Brien Drive

Menlo Park, CA 94025

833-694-2553

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Others